KR20240045281A - Her3 항원 결합 분자를 사용한 암 치료 및 예방 - Google Patents

Her3 항원 결합 분자를 사용한 암 치료 및 예방 Download PDF

Info

Publication number
KR20240045281A
KR20240045281A KR1020247007953A KR20247007953A KR20240045281A KR 20240045281 A KR20240045281 A KR 20240045281A KR 1020247007953 A KR1020247007953 A KR 1020247007953A KR 20247007953 A KR20247007953 A KR 20247007953A KR 20240045281 A KR20240045281 A KR 20240045281A
Authority
KR
South Korea
Prior art keywords
her3
cancer
mutation
contain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007953A
Other languages
English (en)
Korean (ko)
Inventor
제롬 더글라스 보이드-커크업
슈레야 카르
콘래드 파스키에비치
딥티 타카르
피어스 잉그램
Original Assignee
허밍버드 바이오사이언스 피티이. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허밍버드 바이오사이언스 피티이. 엘티디. filed Critical 허밍버드 바이오사이언스 피티이. 엘티디.
Publication of KR20240045281A publication Critical patent/KR20240045281A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020247007953A 2021-08-13 2022-08-12 Her3 항원 결합 분자를 사용한 암 치료 및 예방 Pending KR20240045281A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232883P 2021-08-13 2021-08-13
US63/232,883 2021-08-13
PCT/EP2022/072674 WO2023017151A1 (en) 2021-08-13 2022-08-12 Treatment and prevention of cancer using her3 antigen-binding molecules

Publications (1)

Publication Number Publication Date
KR20240045281A true KR20240045281A (ko) 2024-04-05

Family

ID=83228993

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007953A Pending KR20240045281A (ko) 2021-08-13 2022-08-12 Her3 항원 결합 분자를 사용한 암 치료 및 예방

Country Status (6)

Country Link
US (1) US20250136712A1 (https=)
EP (1) EP4384640A1 (https=)
JP (1) JP2024529141A (https=)
KR (1) KR20240045281A (https=)
CN (1) CN118119719A (https=)
WO (1) WO2023017151A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
WO2025056781A1 (en) * 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer
JP2020533269A (ja) * 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
WO2023017151A9 (en) 2024-06-06
WO2023017151A1 (en) 2023-02-16
EP4384640A1 (en) 2024-06-19
CN118119719A (zh) 2024-05-31
JP2024529141A (ja) 2024-08-01
US20250136712A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
JP6449308B2 (ja) がんバイオマーカー及びその使用
JP2023103258A (ja) がんの治療法及び診断法
Nahta et al. Herceptin: mechanisms of action and resistance
JP2022172083A (ja) 癌のための治療方法及び診断方法
Ricciardi et al. NSCLC and HER2: between lights and shadows
JP2025081454A (ja) 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
KR20130103734A (ko) 바이오마커 및 치료 방법
JP2024167282A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
JP2021502066A (ja) がんの診断及び療法
TW201837467A (zh) 用於癌症之診斷及治療方法
TW201819640A (zh) 癌症之治療性及診斷性方法
MX2007012570A (es) Terapia de anticuerpo anti-egfr basada en un numero de copia creciente del gen egfr en tejidos de tumor.
CN112912403A (zh) 治疗肿瘤的方法
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
US20240101707A1 (en) A method of preventing, alleviating or treating a tumor
CN113891748A (zh) 治疗肿瘤的方法
CN112292151B (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN117321418A (zh) 癌症生物标志物及其使用方法
US20250136712A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
Krawczyk et al. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
Dedić Plavetić et al. Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications
JP2023520515A (ja) がんに対する治療方法及び診断方法
KR20260026009A (ko) Her3 항원 결합 분자를 이용한 암의 치료 및 예방
JP2026513904A (ja) Ｈｅｒ３抗原結合分子を使用する、がんの処置および予防
JP6512828B2 (ja) ｃ−Ｍｅｔ阻害剤の効能予測または効能検証のためのバイオマーカー

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000